

# Brilliant Violet 421™ anti-human FcεRIα

**Catalog # /** 2273120 / 100 tests

**Size:** 2273115 / 25 tests

**Clone:** AER-37 (CRA-1)


**Isotype:** Mouse IgG2b, κ

**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 421™ and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

**Concentration:** Lot-specific




Human peripheral blood lymphocytes were stained with CD203c APC and FcεRIα (clone AER-37) Brilliant Violet 421™ (top) or mouse IgG2b, κ Brilliant Violet 421™ isotype control (bottom).

## Applications:

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.



Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

**Application Notes:** Clone AER-37 (CRA-1) has been reported to bind the receptor even in the presence of IgE.<sup>4</sup>

**Application References:**

1. Yamaguchi M, *et al.* 1999. *J. Immunol.* 162:5455.
2. Suzukawa M, *et al.* 2005. *Int. Immunol.* 17:1249.
3. Charles N, *et al.* 2010. *Nat. Med.* 16:701. (FC) [PubMed](#)
4. Yamaguchi M, *et al.* 1999. *J. Immunol.* 162:5455.

---

**Description:** High affinity IgE receptor (FcεRI) plays a key role in IgE-mediated allergic immune response. FcεRI is a tetrameric receptor complex, which is composed of one α-subunit (FcεRIα), one β-subunit, and two γ-subunits. FcεRIα directly binds IgE with high affinity, while the β- and γ-chains are responsible for mediating intracellular signals. FcεRIα is a 50 kD transmembrane protein with Ig superfamily structure. It is primarily found on mast cells and basophils. Further studies have indicated that FcεRIα is also expressed on many inflammatory cells including cutaneous Langerhans cells, dendritic cells, monocytes of patients with allergic disorders, platelets, bronchial epithelial cells, eosinophils produced in hypereosinophilic syndrome, and neutrophils from allergy-induced asthma patients.

**Antigen References:**

1. Riske F, *et al.* 1991. *J. Biol. Chem.* 266:11245
2. Gounni AS, *et al.* 2001. *FASEB J.* 15:940.
3. Maurer D, *et al.* 1996. *J. Immunol.* 157:607
4. Maurer d, *et al.* 1994. *J. E*